The main purpose of Core A is to provide essential administrative support for all Program Project related activities as well as to serve as the liaison between Dr. Falck (Consortium Agreement with the University of Texas) and Program Project Investigators. This Core will provide scientific, administrative, budgetary, logistic and biostatistical oversight to all components of the Program Project. The Core personnel: Dr. Schwartzman, Program Director, Core Leader;Ms. Jenks, administrator and Ms. Brown, administrative assistant will 1) facilitate communication among investigators regarding administrative and budgetary issues, allocation of funds and providing accounting updates to investigators;2) provide clerical and administrative support;3) coordinate the projects with our consultant and consortium partners;4) organize meetings among Project Leaders and External and Internal Advisory Committees and provide biostatistical support. The Core Leader is responsible for coordination, integration and administration of procedures, and will ensure compliance with institutional and federal regulatory agencies. The Core Leader will also ensure the thematic progress and the continuous interactive collaboration among investigators ofthis Program Project. Included in Core A is the Consortium Agreement with Dr. Falck (The University of Texas). Dr. Falck is the leading medicinal chemist in the area of cytochrome P450-derived eicosanoids. Under Dr. Falck's contractual agreement, he will continue to supply the Program Project Investigators with chemical synthesis of eicosanoid analogs and cytochrome P450 enzymatic inhibitors. The continuous development of novel analogs with greater efficacy and solubility for in vitro and in vivo studies and the supply of these compounds on a regular basis is critical for the execution and completion of the proposed studies in all three projects.
This Core is critical to the administrative, budgetary, clerical and biostatistical aspects of this grant. This Core provides administrative logistics for coordination among Project Leaders, consultants, consortium partners and External and Internal Advisory Committees. Core A includes the consortium with Dr. Falck for the supply of eicosanoid analogs which are critical tools for all the proposed studies under this Program Project Grant.
|Wu, Cheng-Chia; Gupta, Tanush; Garcia, Victor et al. (2014) 20-HETE and blood pressure regulation: clinical implications. Cardiol Rev 22:1-12|
|Abraham, Nader G; Sodhi, Komal; Silvis, Anne M et al. (2014) CYP2J2 targeting to endothelial cells attenuates adiposity and vascular dysfunction in mice fed a high-fat diet by reprogramming adipocyte phenotype. Hypertension 64:1352-61|
|Capdevila, Jorge H; Pidkovka, Nataliya; Mei, Shaojun et al. (2014) The Cyp2c44 epoxygenase regulates epithelial sodium channel activity and the blood pressure responses to increased dietary salt. J Biol Chem 289:4377-86|
|Hinds Jr, Terry D; Sodhi, Komal; Meadows, Charles et al. (2014) Increased HO-1 levels ameliorate fatty liver development through a reduction of heme and recruitment of FGF21. Obesity (Silver Spring) 22:705-12|
|Cheng, Jennifer; Edin, Matthew L; Hoopes, Samantha L et al. (2014) Vascular characterization of mice with endothelial expression of cytochrome P450 4F2. FASEB J 28:2915-31|
|Hao, Shoujin; Bellner, Lars; Zhao, Hong et al. (2014) NFAT5 is protective against ischemic acute kidney injury. Hypertension 63:e46-52|
|Chen, Li; Ackerman, Rachel; Saleh, Mohamed et al. (2014) 20-HETE regulates the angiogenic functions of human endothelial progenitor cells and contributes to angiogenesis in vivo. J Pharmacol Exp Ther 348:442-51|
|Issan, Yossi; Kornowski, Ran; Aravot, Dan et al. (2014) Heme oxygenase-1 induction improves cardiac function following myocardial ischemia by reducing oxidative stress. PLoS One 9:e92246|
|Wang, Wen-Hui; Zhang, Chengbiao; Lin, Dao-Hong et al. (2014) Cyp2c44 epoxygenase in the collecting duct is essential for the high K+ intake-induced antihypertensive effect. Am J Physiol Renal Physiol 307:F453-60|
|Sodhi, K; Puri, N; Kim, D H et al. (2014) PPARýý binding to heme oxygenase 1 promoter prevents angiotensin II-induced adipocyte dysfunction in Goldblatt hypertensive rats. Int J Obes (Lond) 38:456-65|
Showing the most recent 10 out of 371 publications